Premium
Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy
Author(s) -
Carlberg Valerie M.,
Davies Olivia M. T.,
BrandlingBennett Heather A.,
Leary Sarah E. S.,
Huang Jennifer T.,
Coughlin Carrie C.,
Gupta Deepti
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14495
Subject(s) - medicine , discontinuation , adverse effect , targeted therapy , cancer therapy , pediatric cancer , dermatology , cancer , skin cancer , quality of life (healthcare) , intensive care medicine , nursing
Cancer remains a leading cause of morbidity and mortality among children. Targeted therapies may improve survivorship; however, unique side‐effect profiles have also emerged with these novel therapies. Changes in hair, skin, and nails—termed dermatologic adverse events (AEs)—are among the most common sequelae and may result in interruption or discontinuation of therapy. Though dermatologic AEs have been detailed in adults, these findings are not well described in the pediatric population. We reviewed the literature to characterize dermatologic AEs to anticancer targeted therapies available as of July 2020 and summarized the spectrum of clinical findings as well as treatment recommendations for children. Dermatologic AEs are among the most common AEs reported in pediatric patients receiving targeted therapy, but morphologic and histologic descriptions are often lacking in current publications. Pediatric dermatologists are uniquely poised to recognize specific morphology of dermatologic AEs and make recommendations for prevention and treatment that may improve quality of life and enable ongoing cancer therapy.